"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial".

Fiche publication

Date publication

mai 2020

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme , Pr MANFREDI Sylvain

Tous les auteurs :
Taïeb J, Benhaim L, Laurent Puig P, Le Malicot K, Emile JF, Geillon F, Tougeron D, Manfredi S, Chauvenet M, Taly V, Lepage C, André T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32482534

Résumé

Adjuvant treatment for stage II colon cancer remains debated. Finding a tool to select patients at risk for disease recurrence may help the clinical decision. Circulating tumor DNA (ctDNA) has been reported recently as a potential predictive marker for disease recurrence. We thus aim to test its ability to better select stage II colon cancer patients for adjuvant therapy.